2019 in limericks: The highs and lows from the life sciences – STAT
To mark the highs and lows of 2019, STAT is continuing its annual tradition: the life-science year in review in limericks.
Related Articles
From rapid cooling body bags to ‘prescriptions’ for AC, doctors prepare for a future of extreme heat
From body bags for rapid cooling to “prescriptions” for air conditioners, doctors are preparing for a future of extreme heat linked to climate change.
Hearing aids may slow mental decline in those at higher risk of dementia, study finds
New research ties hearing aids to slower cognitive decline in those at higher risk of dementia.
Johnson & Johnson sues to stop Medicare negotiation
Pharmaceutical giant Johnson & Johnson is the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.
‘Doctors need to get on top of this’: GPT-4 displays bias in medical tasks
“GPT-4, being trained off of our own textual communication, shows the same — or maybe even more exaggerated — racial and sex biases as humans”…
Flagship, Pfizer team up in deal worth up to $7 billion
The new Pfizer partnership with Flagship will fund the development of up to 10 drug candidates.
STAT Virtual Event: The State of Biosimilars: What to Watch
Join STAT for a discussion of what’s next for biosimilars, and what key signals will indicate how they might be prescribed, or paid for.
As digital health tech proliferates, a new institute aims to cut through hype
“Increasingly, I think patients, health insurers, providers and even investors are really saying, ‘How do we make sure digital health tools work, and what does…
From rapid cooling body bags to ‘prescriptions’ for AC, doctors prepare for a future of extreme heat
From body bags for rapid cooling to “prescriptions” for air conditioners, doctors are preparing for a future of extreme heat linked to climate change.
Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing
For the third time this year, Novartis has been rebuked by a U.K. trade group for misleading promotional efforts for its biggest-selling drug.
Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing
For the third time this year, Novartis has been rebuked by a U.K. trade group for misleading promotional efforts for its biggest-selling drug.